This is a 76-week trial comparing semaglutide 2.4 mg taken once weekly with liraglutide 3.0 mg taken once daily as an adjunct to a reduced-calorie diet and increased physical activity in subjects with overweight or obesity . This is a randomized, double-blinded trial. Each active medication will be compared against a placebo and be administered per a dosing schedule.
NNC0174-0833 is a long acting medication that has been studied for management of diabetes. These trials showed a weight loss effect, so it is being studied here as a possible means of weight management treatment. The study seeks to determine the dose of NNC0174-0833, a long acting medication, which may be most effective for weight management for people suffering from overweight or obesity. This study is over a period of 26 weeks along with a 7-week follow-up period. Five doses of NNC0174-0833 will be compared against the drug liraglutide 3.0 mg and an inactive placebo.
Participants will be randomly assigned to receive one of these drugs. All participants will receive diet and physical activity counseling. Participants will inject themselves once-weekly or once-daily with study medication. The primary measure of the study will be weight change, body measurement, blood sugar measurement and safety and tolerability of the drug.